RPRX 250117 27.50C (RPRX250117C27500) Stock Options, News & Quotes - Moomoo

US OptionsDetailed Quotes

RPRX250117C27500

Watchlist

3.40
+0.04+1.19%

15min DelayClose Jan 17 16:00 ET

3.40High2.50Low

Intraday

5D
Daily

News

Royalty Pharma Plc's (NASDAQ:RPRX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Simply Wall StJan 16 08:07 ET
Royalty Pharma Plc (RPRX): Analysts Recommend This 52-Week High Stocks Now
Yahoo FinanceJan 15 13:52 ET
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42
Moomoo NewsJan 14 08:34 ET · Ratings
TD Cowen Initiates Royalty Pharma(RPRX.US) With Buy Rating, Announces Target Price $42
Moomoo NewsJan 13 17:31 ET · Ratings
Royalty Pharma's Strategic Acquisition and Share Buyback Boosts Growth Outlook
TipRanksJan 13 17:15 ET
Royalty Pharma Announces 2024 Achievements and Strategic Plans
TipRanksJan 13 09:06 ET

Comments

$Royalty Pharma (RPRX.US)$

$Royalty Pharma (RPRX.US)$

Dec 23, 2024 11:01

$Royalty Pharma (RPRX.US)$

Nov 4, 2024 15:05

$Syndax Pharmaceuticals (SNDX.US)$ $Royalty Pharma (RPRX.US)$ Press Release: Syndax Pharmaceuticals and Royalty Pharma Enter Into $350 Million Royalty Funding Agreement for Niktimvo(TM)
Dow Jones· 1 min ago

Feb 22, 2024 04:36

Unusual items boosting Royalty Pharma's profit may not recur, possibly causing a profit drop this year. The company's statutory earnings may not truly reflect its underlying earnings power. Investors should note 4 warning signs for Royalty Pharma.

There May Be Underlying Issues With The Quality Of Royalty Pharma's (NASDAQ:RPRX) Earnings

Read more